Sub menu

 
 

Authorised Prescriber established history of use lists

Check the list of medicines you can prescribe through the established history of use pathway as an Authorised Prescriber.

We are updating our content for unapproved therapeutic goods. Please give your feedback.

If the medicine you want to access is on the lists, you can apply to become an Authorised Prescriber through the established history of use pathway. 

You must meet all the listed criteria to prescribe the product.

To apply, submit the form in the online system.

SAS and AP online system


Biologicals or medical devices aren't on the established history of use lists.

To access these products, use the standard pathway.

Read more about unapproved products for multiple patients (Authorised Prescriber).

Authorised Prescriber established history of use products

Active ingredient

 Dosage form Route of administration Indication Code
Allergens—multiple, various (including control solutions) Drops Intradermal Confirmation of suspected allergic reactions AP2
Allergens – multiple, various (including control solutions) Drops Skin prick Confirmation of suspected allergic reactions AP3
Argipressin Injection Intravenous To increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines AP147
Argipressin Injection Intravenous Treatment of uterine fibroids AP157
Amiloride Tablet Oral Treatment of hypokalemia AP158
Betaxolol 0.25% (preservative free) Eye drops  Ophthalmic Treatment of elevated intraocular pressure where other treatments are inappropriate AP5
Bismuth subcitrate Tablet Oral Treatment of resistant Helicobacter Pylori infection AP6
Buspirone Tablet Oral Treatment of generalised anxiety disorders AP7
Calcitriol Liquid Oral Prevention of hypophosphatemic rickets in children AP8
Calcitriol Liquid Oral Treatment of hypoparathyroidism (with severe hypocalcaemia) AP9
Carbidopa Tablet Oral Premedication for F‑18 DOPA imaging AP10
Ciclosporin, 0.05% Eye drops, emulsion Ophthalmic Treatment of suppressed tear production due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye syndrome) AP26
Cinnarizine Tablet Oral Treatment of vestibular disorders such as vertigo, tinnitus, nausea and vomiting (including Meniere’s disease)  AP13
Clobetasol propionate 0.05% Cream Topical Treatment, or prolongation of flare‑free intervals, of dermatitis/eczema where other treatments have failed AP14
Clobetasol propionate 0.05% Lotion Topical Treatment, or prolongation of flare‑free intervals, of dermatitis/eczema where other treatments have failed AP15
Clobetasol propionate 0.05% Ointment Topical Treatment, or prolongation of flare‑free intervals, of dermatitis/eczema where other treatments have failed AP16
Clofazimine Capsule Oral Treatment of Leprosy AP17
Clofazimine Capsule Oral Treatment of granulomatous cheilitis AP18
Clofazimine Capsule Oral Treatment of Melkersson Rosenthal Syndrome AP19
Clofazimine Capsule Oral Treatment of confirmed mycobacterium avium paratuberculosis in immunocompromised patients recommended by an infectious disease specialist AP20
Clofazimine Capsule Oral Treatment of erythema nodosum leprosum AP21
Clofazimine Capsule Oral Treatment of drug resistant tuberculosis AP22
Clofazimine Capsule Oral Treatment of non-tuberculosis mycobacterial infections AP23
Clofazimine Capsule Oral Treatment of other infections as recommended by an infectious diseases specialist AP24
Colecalciferol Capsule Oral Treatment of severe vitamin D deficiency and prevention of osteoporosis AP11
Colecalciferol Injection  Intramuscular Treatment of severe vitamin D deficiency and prevention of osteoporosis AP12
Cyclopentolate, 0.2%, and phenylephrine, 1% Eye drops Ophthalmic Production of mydriasis AP25
Deflazacort Tablet Oral Treatment of Duchenne muscular dystrophy AP27
Dehydrated ethanol (alcohol) 96% ‑ 100% Ampoule Topical Treatment of progressive keratoconus and intra‑operative use in superficial keratectomy (single use per procedure) AP28
Dexamethasone (preservative free) Eye drops Ophthalmic Treatment of inflammatory conditions of the eye that are non‑infected and steroid responsive in patients sensitive to preservative‑containing formulations AP29
Diazoxide Capsule Oral Treatment of hypoglycaemia AP30
Diazoxide Capsule Oral Treatment of hyperinsulinaemia  AP31
Diazoxide Capsule Oral Treatment of Beckwith-Weiderman Syndrome AP32
Diazoxide Capsule Oral Treatment of insulinoma AP33
Diazoxide Suspension Oral Treatment of hypoglycaemia AP34
Diazoxide Suspension Oral Treatment of hyperinsulinaemia AP35
Diazoxide Suspension Oral Treatment of Beckwith-Weiderman Syndrome AP36
Diazoxide Suspension Oral Treatment of insulinoma AP37
Diazoxide Tablet  Oral Treatment of hypoglycaemia AP38
Diazoxide Tablet  Oral Treatment of hyperinsulinaemia AP39
Diazoxide Tablet  Oral Treatment of Beckwith-Weiderman Syndrome AP40
Diazoxide Tablet Oral Treatment of insulinoma AP41
Diflunisal Tablet Oral Treatment of amyloidosis AP42
Dimethyl sulfoxide (DMSO) Solution Intravesical Symptomatic relief of interstitial cystitis AP43
Disulfiram Tablet Oral Deterrent to alcohol consumption AP148
Doxycycline Injection Intralesional Sclerotherapy of lymphatic malformations AP44
F‑18 DCFPyl (PSMA) Injection Intravenous Prostate cancer imaging study AP45
F‑18 myocardial perfusion tracer (18F flurpiridaz) Injection Intravenous Myocardial perfusion study AP46
F‑18 NaF (sodium fluoride) Injection Intravenous Bone study AP47
Famotidine Injection Intravenous Prevention and management of hypersensitivity reactions to chemotherapy AP149
Flunarizine Tablet Oral Treatment of vestibular disorders AP48
Flunarizine Tablet Oral Prophylactic treatment of migraine AP49
Flunarizine Capsule Oral Treatment of vestibular disorders AP50
Flunarizine Capsule Oral Prophylactic treatment of migraine AP51
Furazolidone Tablet Oral Treatment of resistant Helicobacter Pylori infection AP52
Gallium‑68 Aerosol Inhalation Lung ventilation study AP53
Ga‑68 - Galligas Aerosol Inhalation Lung ventilation study AP53
Gallium‑68 Injection Intravenous Lung perfusion study AP54
Ga‑68 ‑ MAA Injection Intravenous Lung perfusion study AP54
Gallium‑68 prostate specific membrane antigen (PSMA) Injection Intravenous Prostate cancer imaging study AP55
Gallium‑68 prostate specific membrane antigen (PSMA) Injection Intravenous PET CT gallium-68 PSMA whole body uptake study AP159
Ganciclovir Gel Ophthalmic Treatment of cytomegalovirus AP160
Glycopyrronium bromide Tablet Oral Treatment of excessive salivation in patients with neurological conditions AP56
Hyoscine hydrobromide Patch Transdermal Treatment of excessive salivation AP57
Hypertonic sodium chloride, 5 % Eye ointment Ophthalmic Temporary relief of corneal oedema (hypertonicity) AP58
Hypertonic sodium chloride, 5% Eye drops Ophthalmic Temporary relief of corneal oedema (hypertonicity) AP59
Iloprost Injection Intravenous infusion Treatment of patients with severe disabling Raynaud's phenomenon  AP150
Iloprost Injection Intravenous infusion Treatment of peripheral ischaemia AP151
Indigo carmine Injection Intravenous Intraoperative detection of suspected urethral injuries during abdominal and pelvic surgical procedures AP60
Indocyanine green dye Injection Intravenous Intra‑operative diagnostic use AP61
Interferon alpha‑2b Eye drops Ophthalmic Treatment of ocular surface squamous neoplasia AP152
Ketotifen Tablet Oral Treatment of allergic conditions AP62
Levofloxacin Tablet Oral Treatment of resistant Helicobacter Pylori infection AP63
Levofloxacin Tablet Oral Treatment of drug resistant tuberculosis AP64
Levomepromazine Tablet Oral Treatment of nausea and vomiting AP65
Levomepromazine Tablet Oral Treatment of agitation AP66
Levomepromazine Injection Subcutaneous Treatment of nausea and vomiting AP67
Levomepromazine Injection Subcutaneous Treatment of agitation AP68
Lifitegrast Eye drops Ophthalmic Treatment of dry eye disease AP153
Lutetium‑177 (Lu 177) dotatate Injection Intravenous Treatment of somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) AP154
Lutetium‑177(Lu 177) Prostate Specific Membrane Antigen (PSMA) Injection Intravenous Treatment of metastatic castration‑resistant prostate cancer AP155
Melatonin Syrup Oral Treatment of sleep disorders AP70
Melatonin Capsule Oral Treatment of sleep disorders AP71
Melatonin Immediate release tablet Oral Treatment of sleep disorders AP72
Melatonin Lozenge Oral Treatment of sleep disorders AP73
Metolazone Tablet Oral Treatment of fluid overlaod AP161
Mexiletine Tablet Oral Treatment of ventricular arrhythmia AP74
Mexiletine Tablet Oral Treatment of myotonic disorders AP75
Mexiletine Capsule Oral Treatment of ventricular arrhythmia AP76
Mexiletine Capsule Oral Treatment of myotonic disorders AP77
Moxifloxacin 0.5% Eye drops Ophthalmic Treatment of refractory bacterial conjunctivitis AP78
Nadolol Tablet Oral Treatment of ventricular tachycardia AP79
Nadolol Tablet Oral Treatment of long QT Syndrome AP80
Natamycin 5% Eye drops Ophthalmic Treatment of refractory fungal blepharitis, conjunctivitis or keratitis AP81
Neomycin Tablet Oral Sepsis prevention for colorectal operation AP82
Nicotine in solution, salt or base form Liquid or solid Inhalation Smoking cessation AP83
Nifedipine Immediate release tablet Oral Treatment of preterm labour  AP156
Nifedipine Immediate release tablet Oral Treatment of pre‑eclampsia AP141
Nifedipine Capsule Oral Treatment of preterm labour  AP142
Nifedipine Capsule Oral Treatment of pre‑eclampsia AP143
Nitazoxanide Tablet Oral Treatment of giardiasis AP84
Nitazoxanide Tablet Oral Treatment of cryptosporidiosis AP85
Nitazoxanide Tablet Oral Treatment of blastocystis AP86
Nitazoxanide Suspension Oral Treatment of giardiasis AP87
Nitazoxanide Suspension Oral Treatment of cryptosporidiosis AP88
Nitazoxanide Suspension Oral Treatment of blastocystis AP89
Paromomycin Capsule Oral Antiprotozoal treatment of Blastocystis hominis AP90
Paromomycin Capsule Oral Antiprotozoal treatment of Dientomoeba fragilis AP91
Paromomycin Capsule Oral Antiprotozoal treatment of Entamoeba histolytica AP92
Paromomycin Capsule Oral Antiprotozoal treatment of any of parasite infection AP93
Pimozide Tablet Oral Treatment of schizophrenia AP94
Pimozide Tablet Oral Treatment of chronic psychosis AP95
Pimozide Tablet Oral Treatment of Tourette syndrome AP96
Pristinamycin Tablet Oral Treatment of confirmed methicillin‑resistant Staphylococcus aureus or vancomycin‑resistant enterococci infection where there is history of failed therapy with the other available antibiotics, at sites in relation to bone/joint/prosthesis AP97
Pristinamycin Tablet Oral Treatment of refractory or resistant mycoplasma genitalium infections AP98
Pristinamycin Tablet Oral Treatment of other infections as prescribed by an infectious disease specialist AP99
Progesterone Injection Subcutaneous Treatment of progesterone deficiency AP144
Progesterone in oil Injection Intramuscular Treatment of progesterone deficiency AP145
Pyrazinamide Tablet Oral Treatment of tuberculosis AP100
Riboflavin, 0.1% in 20% dextran Eye drops Ophthalmic Intraoperative use in corneal collagen crosslinking (CXL) procedures for the treatment of progressive keratoconus AP101
Riboflavin, 0.1% in 1.1% hydroxylpropyl methylcellulose (HPMC) Eye drops Ophthalmic Intraoperative use in corneal collagen crosslinking (CXL) procedures for the treatment of progressive keratoconus AP102
Riboflavin, 0.1% in sodium chloride Eye drops Ophthalmic Intraoperative use in corneal collagen crosslinking (CXL) procedures for the treatment of progressive keratoconus AP103
Riboflavin, 0.22% in sodium chloride Eye drops Ophthalmic Intraoperative use in corneal collagen crosslinking (CXL) procedures for the treatment of progressive keratoconus AP104
Ripasudil 0.4% Eye drops Ophthalmic Treatment of refractory corneal oedema AP105
Ripasudil 0.4% Eye drops Ophthalmic Treatment of refractory glaucoma AP106
Sodium benzoate Tablet Oral Treatment of urea cycle disorders AP107
Tacrolimus 0.03% Ointment Topical Treatment, or prolongation of flare‑free intervals, of moderate to severe atopic dermatitis/eczema in children AP108
Tacrolimus 0.1% Ointment Topical Treatment, or prolongation of flare‑free intervals, of moderate to severe atopic dermatitis/eczema in adults AP109
Technetium‑99m (99m Tc) Prostate Specific Membrane Antigen (PSMA) Injection Intravenous Prostate cancer imaging study AP146
Tetracycline Capsule Oral Treatment of resistant Helicobacter Pylori infection AP110
Tetracycline Tablet Oral Treatment of resistant Helicobacter Pylori infection AP111
Tick‑borne encephalitis vaccine Injection Intramuscular Prevention of tick‑borne encephalitis AP112
Tinidazole Tablet Oral Treatment of trichomonas vaginalis infections of the genito‑urinary tract in female and male patients AP113
Tinidazole Tablet Oral Treatment of giardiasis AP114
Tinidazole Tablet Oral Treatment of amoebic dysentery AP115
Tinidazole Tablet Oral Treatment of amoebic liver abscess AP116
Tinidazole Tablet Oral Treatment of acute giardiasis in children AP117
Tinidazole Tablet Oral Treatment of acute amoebic dysentery in children AP118
Tinidazole Tablet Oral Treatment of amoebic liver disease in children AP119
Tinidazole Tablet Oral Prevention of infection of the surgical site AP120
Tizanidine Capsule Oral Treatment of spasticity where other treatments have failed AP121
Tizanidine Tablet Oral Treatment of spasticity where other treatments have failed AP122
Triamcinolone acetonide Suspension for injection Ophthalmic Treatment of non‑infectious uveitis AP123
Triamcinolone acetonide Suspension for injection Ophthalmic Visualisation during vitrectomy AP124
Triamcinolone acetonide Suspension for injection Ophthalmic Treatment of diabetic macular oedema AP125
Triamcinolone acetonide Suspension for injection Ophthalmic Treatment of cystoid macular oedema secondary to retinal vein occlusion AP126
Triamcinolone acetonide Suspension for injection Ophthalmic Treatment of uveitic macular oedema AP127
Triamcinolone acetonide Suspension for injection Ophthalmic Treatment of post‑operative macular oedema (cataract surgery) AP128
Verteporfin Powder for injection Intravenous infusion Photosensitisation for photodynamic therapy AP129
Yttrium‑90 (Y‑90) Citrate Injection Intraarticular Radiosynovectomy treatment AP130

Medicinal cannabis products

Active ingredient category and circumstances Dosage form Route of administration Indication Code

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 liquid oral Treatment of refractory chronic pain in adult patients AP131

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 liquid oral Treatment of refractory anxiety in adult patients AP132

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 capsule oral Treatment of refractory chronic pain in adult patients AP133

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 capsule oral Treatment of refractory anxiety in adult patients AP134

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 liquid oral Treatment of refractory chronic pain in adult patients AP135

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 liquid oral Treatment of refractory anxiety in adult patients AP136

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 capsule oral Treatment of refractory chronic pain in adult patients AP137

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 capsule oral Treatment of refractory anxiety in adult patients AP138

Category 3: Balanced medicinal cannabis product (CBD <60% and ≥40%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 40% or more and less than 60% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 liquid oral Treatment of refractory chronic pain in adult patients AP139

Category 3: Balanced medicinal cannabis product (CBD <60% and ≥40%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 40% or more and less than 60% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
 capsule oral Treatment of refractory chronic pain in adult patients AP140
Topics

Help us improve the Therapeutic Goods Administration site